DOI: 10.1186/s13550-018-0364-xPages: 1-2

It is time to move forward into the era of Theranostics

1. University Hospital Bonn, Department of Nuclear Medicine

Correspondence to:
Hojjat Ahmadzadehfar
Tel: +49 228 287 19858
Email: hojjat.ahmadzadehfar@ukbonn.de

Close

Abstract

Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combination or as an alternative to other therapies. Therefore there is a need to train Nuclear Oncologists, who are able to approach oncological diseases, promote development of radiopharmacy, understand the biology of radionuclide treatment, apply radionuclide treatments and be able to use molecular imaging such as PET/CT and SPECT/CT for treatment planning and dosimetry.

This article is freely available, click here to access the full text/PDF

  • Accepted: Jan 22, 2018
  • Online: Jan 30, 2018

Article Tools

eanm
EJNMMI Ad